JP2022512538A5 - - Google Patents
Info
- Publication number
- JP2022512538A5 JP2022512538A5 JP2021510452A JP2021510452A JP2022512538A5 JP 2022512538 A5 JP2022512538 A5 JP 2022512538A5 JP 2021510452 A JP2021510452 A JP 2021510452A JP 2021510452 A JP2021510452 A JP 2021510452A JP 2022512538 A5 JP2022512538 A5 JP 2022512538A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771653P | 2018-11-27 | 2018-11-27 | |
| US62/771,653 | 2018-11-27 | ||
| PCT/US2019/063310 WO2020112815A1 (en) | 2018-11-27 | 2019-11-26 | Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512538A JP2022512538A (ja) | 2022-02-07 |
| JPWO2020112815A5 JPWO2020112815A5 (https=) | 2022-12-05 |
| JP2022512538A5 true JP2022512538A5 (https=) | 2022-12-05 |
Family
ID=70854398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510452A Pending JP2022512538A (ja) | 2018-11-27 | 2019-11-26 | Ｅｂｖ関連がんの処置のための抗ｌｍｐ２ ｔｃｒ－ｔ細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12139523B2 (https=) |
| JP (1) | JP2022512538A (https=) |
| KR (1) | KR20210098940A (https=) |
| CN (1) | CN113166224A (https=) |
| SG (1) | SG11202101671PA (https=) |
| TW (1) | TW202039540A (https=) |
| WO (1) | WO2020112815A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| WO2021243695A1 (en) * | 2020-06-05 | 2021-12-09 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Tcr-t cell therapy targeting epstein-barr virus |
| CN112940108B (zh) * | 2021-03-19 | 2022-10-14 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 |
| WO2023092452A1 (zh) * | 2021-11-26 | 2023-06-01 | 上海吉倍生物技术有限公司 | 识别ebv lmp2抗原的t细胞受体及其应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN119390814B (zh) * | 2023-10-26 | 2025-06-27 | 上海市第一人民医院 | 一种t细胞受体及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| US8834889B2 (en) * | 2011-08-29 | 2014-09-16 | National Tsing Hua University | Antigen presenting composition and use thereof |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| WO2016095783A1 (zh) | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
| GB201520191D0 (en) * | 2015-11-16 | 2015-12-30 | Cancer Rec Tech Ltd | T-cell receptor and uses thereof |
| GB201522592D0 (en) * | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| CN106632659A (zh) * | 2016-08-05 | 2017-05-10 | 武汉赛云博生物科技有限公司 | 一种eb病毒特异性tcr及其重组慢病毒载体与应用 |
| CN110139873A (zh) * | 2016-10-03 | 2019-08-16 | 朱诺治疗学股份有限公司 | Hpv特异性结合分子 |
| CN110582509A (zh) * | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
-
2019
- 2019-11-26 US US17/276,553 patent/US12139523B2/en active Active
- 2019-11-26 SG SG11202101671PA patent/SG11202101671PA/en unknown
- 2019-11-26 JP JP2021510452A patent/JP2022512538A/ja active Pending
- 2019-11-26 CN CN201980056915.5A patent/CN113166224A/zh active Pending
- 2019-11-26 KR KR1020217005780A patent/KR20210098940A/ko not_active Ceased
- 2019-11-26 WO PCT/US2019/063310 patent/WO2020112815A1/en not_active Ceased
- 2019-11-27 TW TW108143260A patent/TW202039540A/zh unknown